Начало・Списък с акции・Allogene Therapeutics Inc

Allogene Therapeutics Inc

Затворен

СекторЗдравеопазване

2 2.04

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.95

Максимум

2.02

Ключови измерители
By Trading Economics
Приходи	-3.8M -43M
EPS	-0.18
Служители	150
EBITDA	-91K -39M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+407.61% upside

Дивиденти
By Acuity
Следващи печалби	12.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-152M 635M
Предишно отваряне	-0.04
Предишно затваряне	2

Allogene Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.08.2026 г., 19:16 ч. UTC

Correlated Moves

Biotechnology stocks are rising, boosting Allogene Therapeutics shares. The ARK Genomic Revolution ETF has also increased, reflecting positive sector momentum.

6.08.2026 г., 19:46 ч. UTC

Correlated Moves

Allogene Therapeutics shares are lower, reflecting broader market trends, as the Russell 2000 Index also declined during Thursday's session.

5.08.2026 г., 22:01 ч. UTC

Allogene Therapeutics Inc shares are lower in after-market trading, reflecting a pullback from earlier gains amid broader market volatility following weaker U.S. job growth data.

3.08.2026 г., 20:06 ч. UTC

Allogene Therapeutics Inc. shares are trading lower, continuing a decline since Friday's close, despite broader market gains in the S&P 500 and Nasdaq 100.

30.07.2026 г., 20:04 ч. UTC

Correlated Moves

Event

Allogene Therapeutics receives RMAT and Fast Track designations from the FDA for cema-cel, contributing to gains in shares today.

29.07.2026 г., 23:51 ч. UTC

Event

Correlated Moves

Allogene Therapeutics receives FDA RMAT and Fast Track designations for cema-cel, boosting shares higher in after-market hours. The Russell 2000 Index's rise may also contribute.

28.07.2026 г., 20:02 ч. UTC

Allogene Therapeutics Inc shares are lower amid negative market sentiment following a significant sell-off in technology stocks across Asian markets.

27.07.2026 г., 18:07 ч. UTC

Allogene Therapeutics Inc shares are higher today, despite earlier fluctuations. The market backdrop features a decline in oil prices, easing inflation concerns.

24.07.2026 г., 19:46 ч. UTC

Correlated Moves

Allogene Therapeutics Inc is lower today amid broader market declines, with the Russell 2000 Index down and oil price volatility impacting the biotechnology sector.

23.07.2026 г., 22:56 ч. UTC

Allogene Therapeutics Inc. shares are roughly flat in after-market trading, remaining below their 20-day moving average and near the lower end of their one-month range.

22.07.2026 г., 20:13 ч. UTC

Correlated Moves

Allogene Therapeutics Inc shares are lower in after-market trading, reflecting broader market declines amid rising crude oil prices and geopolitical tensions.

21.07.2026 г., 18:46 ч. UTC

Correlated Moves

Social Media

Allogene Therapeutics shares are higher following positive TRAVERSE trial results for ALLO-316, which showed a 25% overall response rate in patients.

20.07.2026 г., 23:26 ч. UTC

Allogene Therapeutics Inc. shares are higher in after-market trading, with no specific news identified. Broader market volatility continues to influence investor sentiment.

Сравнение с други в отрасъла

Ценова промяна

Allogene Therapeutics Inc Прогноза

Ценова цел

By TipRanks

407.61% нагоре

12-месечна прогноза

Среден 10 USD 407.61%

Висок 14 USD

Нисък 7 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Allogene Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Allogene Therapeutics Inc през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.